Eton pharmaceuticals, inc. (ETON)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Dec'17
Assets
Current assets:
Cash and cash equivalents

12,335

12,066

11,777

14,947

19,584

26,735

6,603

13,156

Accounts receivable, net

205

473

-

-

-

-

-

-

Inventory

1,726

380

-

-

-

-

-

-

Prepaid expenses and other current assets

1,075

2,090

330

1,808

1,943

767

-

-

Prepaid expenses

-

-

-

-

-

-

200

136

Total current assets

15,341

15,009

12,107

16,755

21,527

27,502

6,803

13,292

Property and equipment, net

1,025

1,117

1,169

1,223

1,190

773

268

119

Intangible assets, net

688

725

-

-

-

-

-

-

Operating lease right-of-use assets, net

129

160

191

222

252

-

-

-

Other long-term assets, net

58

61

40

44

48

52

454

32

Total assets

17,241

17,072

13,507

18,244

23,017

28,327

7,525

13,443

Liabilities and stockholders' equity
Current liabilities:
Accounts payable

1,183

575

549

883

3,208

1,421

793

539

Accrued liabilities

868

1,388

558

576

448

603

404

254

Total current liabilities

2,051

1,963

1,107

1,459

3,656

2,024

1,197

793

Long-term debt, net of discount and including accrued fees

4,570

4,540

-

-

-

-

-

-

Operating lease liabilities, net of current portion

-

19

52

86

119

-

-

-

Warrant liability

-

-

-

-

-

-

1,577

520

Total liabilities

6,621

6,522

1,159

1,545

3,775

2,024

2,774

1,313

Commitments and contingencies (Note 11)

-

-

-

-

-

-

0

-

Redeemable convertible preferred stock - Series A $0.001 par value, 10,000,000 shares authorized as of December 31, 2018 and 2017; no shares and 6,685,082 shares issued and outstanding as of December 31, 2018 and 2017, respectively; aggregate liquidation preference of $0 and $20,698 as of December 31, 2018 and 2017, respectively

-

-

-

-

-

-

21,161

19,004

Stockholders' equity
Common stock, $0.001 par value; 50,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 20,761,960 and 17,877,486 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

21

18

18

18

18

18

6

6

Additional paid-in capital

83,836

74,720

-

-

-

-

-

-

Additional paid-in capital

-

-

73,822

73,208

72,502

72,153

3,390

1,759

Accumulated deficit

-73,237

-64,188

-61,492

-56,527

-53,278

-45,868

-19,806

-8,639

Total stockholders' equity

10,620

10,550

12,348

16,699

19,242

26,303

-16,410

-6,874

Total liabilities and stockholders' equity

17,241

17,072

13,507

18,244

23,017

28,327

7,525

13,443